MedPath

CHS 828 in Treating Patients With Solid Tumors

Phase 1
Withdrawn
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Registration Number
NCT00003979
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of CHS 828 in treating patients who have solid tumors.

Detailed Description

OBJECTIVES:

* Determine the maximum tolerated dose of oral CHS 828 in patients with solid tumors.

* Determine the qualitative and quantitative toxic effects of this regimen in these patients.

* Determine a safe dose of this regimen for phase II evaluation.

* Determine the pharmacokinetic profile of this regimen in these patients.

* Determine any antitumor activity in these patients.

OUTLINE: Patients receive oral CHS 828 every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of CHS 828 until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity.

Patients are followed for up to 4 weeks.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 12 months.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (28)

Innsbruck Universitaetsklinik

🇦🇹

Innsbruck, Austria

Inselspital, Bern

🇨🇭

Bern, Switzerland

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Vrije Universiteit Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Western General Hospital

🇬🇧

Edinburgh, Scotland, United Kingdom

Ludwig Institute for Cancer Research

🇧🇪

Brussels, Belgium

Antoni van Leeuwenhoekhuis

🇳🇱

Amsterdam, Netherlands

University Hospital

🇨🇭

Basel, Switzerland

Institut Jules Bordet

🇧🇪

Brussels, Belgium

Kantonsspital - St. Gallen

🇨🇭

St. Gallen, Switzerland

Academisch Ziekenhuis Groningen

🇳🇱

Groningen, Netherlands

University Medical Center Nijmegen

🇳🇱

Nijmegen, Netherlands

Erasmus Medical Center

🇳🇱

Rotterdam, Netherlands

C.R.C. Beatson Laboratories

🇬🇧

Glasgow, Scotland, United Kingdom

Ninewells Hospital and Medical School

🇬🇧

Dundee, Scotland, United Kingdom

Herlev Hospital - University Hospital of Copenhagen

🇩🇰

Copenhagen, Denmark

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Institut Gustave Roussy

🇫🇷

Villejuif, France

Kaiser Franz Josef Hospital

🇦🇹

Vienna, Austria

Norwegian Radium Hospital

🇳🇴

Oslo, Norway

Institut Bergonie

🇫🇷

Bordeaux, France

Centre Jean Perrin

🇫🇷

Clermont-Ferrand, France

CRLCC Nantes - Atlantique

🇫🇷

Nantes-Saint Herblain, France

Centre Leon Berard

🇫🇷

Lyon, France

Universitaetsklinik und Strahlenklinik - Essen

🇩🇪

Essen, Germany

Institut Claudius Regaud

🇫🇷

Toulouse, France

Klinikum Nuernberg - Klinikum Nord

🇩🇪

Nuremberg, Germany

Newcastle General Hospital

🇬🇧

Newcastle Upon Tyne, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath